Trevi Therapeutics (NASDAQ:TRVI) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVI) in a report published on Monday,Benzinga reports. The firm currently has a $21.00 target price on the stock.

Several other analysts also recently commented on TRVI. HC Wainwright upped their price objective on Trevi Therapeutics from $6.00 to $7.50 and gave the company a “buy” rating in a research note on Thursday, December 12th. Needham & Company LLC reissued a “buy” rating and issued a $8.00 target price on shares of Trevi Therapeutics in a report on Thursday, December 12th. Eight equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $9.31.

Trevi Therapeutics Stock Performance

NASDAQ TRVI opened at $4.31 on Monday. The firm’s fifty day moving average is $4.09 and its two-hundred day moving average is $3.40. Trevi Therapeutics has a one year low of $2.30 and a one year high of $5.05. The firm has a market cap of $331.31 million, a PE ratio of -9.80 and a beta of 0.88.

Institutional Trading of Trevi Therapeutics

Several hedge funds have recently modified their holdings of the business. Summit Investment Advisors Inc. grew its holdings in Trevi Therapeutics by 84.2% during the fourth quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company’s stock worth $26,000 after acquiring an additional 2,894 shares during the period. BNP Paribas Financial Markets boosted its position in shares of Trevi Therapeutics by 130.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock worth $40,000 after purchasing an additional 6,764 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Trevi Therapeutics during the 4th quarter worth $49,000. Squarepoint Ops LLC purchased a new position in shares of Trevi Therapeutics in the 4th quarter valued at about $58,000. Finally, Intech Investment Management LLC acquired a new stake in shares of Trevi Therapeutics in the third quarter valued at about $63,000. 95.76% of the stock is owned by institutional investors and hedge funds.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.